Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
Authors
Keywords
CRPC, Bone metastasis, μCT imaging, X-ray, BLI, Axitinib, VEGFR crizotinib, c-MET
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-10-03
DOI
10.1186/1471-2407-14-742
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients
- (2011) R. Mehra et al. CLINICAL CANCER RESEARCH
- Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer
- (2011) M. Merino et al. EUROPEAN JOURNAL OF CANCER
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases
- (2011) Marc Colombel et al. PROSTATE
- Novel options for the treatment of castration-resistant prostate cancer
- (2011) Carsten-H. Ohlmann et al. WORLD JOURNAL OF UROLOGY
- Treatment and prevention of bone complications from prostate cancer
- (2010) Richard J. Lee et al. BONE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pathogenesis of osteoblastic bone metastases from prostate cancer
- (2010) Toni Ibrahim et al. CANCER
- A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone
- (2009) Xin Li et al. CANCER RESEARCH
- Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer
- (2009) A. L. Russo et al. CLINICAL CANCER RESEARCH
- Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
- (2009) R. M. Attar et al. CLINICAL CANCER RESEARCH
- Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
- (2009) Kim N. Chi et al. EUROPEAN UROLOGY
- Vascular endothelial growth factor regulates osteoblast survival – evidence for an autocrine feedback mechanism
- (2009) John Street et al. Journal of Orthopaedic Surgery and Research
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started